RxDoctor Payments Data

Matthew Nutaitis, MD

Glaucoma Specialist · Charleston, SCNPI 1548240740

Payments from drug & device makers

$13,327in general payments, 2019–2025

Across 132 payments — averaging $100.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Alcon Research LLC$2K
  • NEW World Medical,inc.$2K
  • Alcon$1K
  • Glaukos Corporation$779
  • Sight Sciences, Inc.$571
  • plus $4K from 20 others

What the payments were for

  • Food & beverage$11,359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$84,473
Medicare patients
257
Services billed
702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost46$25,432
RhopressaNetarsudil Mesylate34$21,316
Brimonidine Tartrate195$10,633
Alphagan PBrimonidine Tartrate22$9,206
RocklatanNetarsudil Mesylat/Latanoprost21$8,865
CombiganBrimonidine Tartrate/Timolol14$7,270
Travoprost18$3,721
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat182$3,464
Acetazolamide ErAcetazolamide48$3,230
Latanoprost318$3,102
Methazolamide12$2,672
Acetazolamide19$1,910
Ketorolac Tromethamine99$1,869
Timolol Maleate141$1,855
Dorzolamide Hcl61$1,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan$3,294$41,90882 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$451$30,18155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Charleston

Where these figures come from

Is this you, or does something look wrong? →